Recent Posts
- Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
- Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
- UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
- Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
- Optimizing AAV Gene Delivery: Hitting the Target Safely and Effectively
AAV One-stop Solution
Tags
AAV2
AAV5
AAV based gene therapy
AAV Capsid
ALS
Alzheimer’s Disease
brain vasculature
cancer
CAR-T
Cell Therapy
COVID-19
COVID vaccine
CRISPR
CRISPR/Cas
Drug Development
dystrophin
eye disease
FDA
gene editing
gene therapy
genetic engineering
genome editing
GMP plasmid
hearing
heart disease
hemophilia
Hemophilia B
hepatitis research
HIV
immunotherapy
liver cancer
mRNA
Neurodegenerative Diseases
Orphan Drug
Parkinson
rare disease
Retinoschisis
RNA
RNAi therapeutics
RNA vaccines
SARS-CoV-2
Sickle Cell Disease
SMA Treatment
thyroid
zolgensma